Paradigm Biocapital Advisors
Latest statistics and disclosures from Paradigm Biocapital Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NUVL, ACLX, ARGX, RVMD, CRNX, and represent 52.18% of Paradigm Biocapital Advisors's stock portfolio.
- Added to shares of these 10 stocks: ACLX (+$80M), VERA (+$49M), MLTX (+$47M), BGNE (+$45M), NUVL (+$44M), JANX (+$38M), SYRE (+$37M), PLRX (+$35M), PCVX (+$32M), KROS (+$31M).
- Started 7 new stock positions in Oruka Therapeutics, KROS, MLTX, VERA, PLRX, SYRE, BGNE.
- Reduced shares in these 10 stocks: SRPT (-$150M), CERE (-$95M), ASND (-$91M), XENE (-$80M), IRON (-$59M), LEGN (-$53M), ARGX (-$31M), OLMA (-$29M), BBIO (-$28M), VRNA (-$10M).
- Sold out of its positions in ALXO, ACRV, ASND, BBIO, CERE, LEGN, SRPT, TCRX, VRNA, VOR. XENE.
- Paradigm Biocapital Advisors was a net seller of stock by $-108M.
- Paradigm Biocapital Advisors has $3.0B in assets under management (AUM), dropping by 13.12%.
- Central Index Key (CIK): 0001855655
Tip: Access up to 7 years of quarterly data
Positions held by Paradigm Biocapital Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Paradigm Biocapital Advisors
Paradigm Biocapital Advisors holds 31 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Nuvalent Inc-a (NUVL) | 17.3 | $512M | +9% | 5.0M | 102.30 |
|
| Arcellx Common Stock Call Option (ACLX) | 13.6 | $401M | +24% | 4.8M | 83.51 |
|
| Argenx Se Sponsored Adr (ARGX) | 8.8 | $260M | -10% | 480k | 542.08 |
|
| Revolution Medicines (RVMD) | 8.2 | $241M | 5.3M | 45.35 |
|
|
| Crinetics Pharmaceuticals In (CRNX) | 4.4 | $129M | 2.5M | 51.10 |
|
|
| Merus N V (MRUS) | 4.1 | $123M | +21% | 2.5M | 49.96 |
|
| Janux Therapeutics (JANX) | 3.7 | $109M | +53% | 2.4M | 45.43 |
|
| Vaxcyte Call Option (PCVX) | 3.5 | $103M | +44% | 905k | 114.27 |
|
| Kura Oncology (KURA) | 2.9 | $85M | -4% | 4.3M | 19.54 |
|
| Tarsus Pharmaceuticals (TARS) | 2.7 | $80M | 2.4M | 32.89 |
|
|
| Edgewise Therapeutics (EWTX) | 2.5 | $74M | +19% | 2.8M | 26.69 |
|
| Disc Medicine (IRON) | 2.5 | $74M | -44% | 1.5M | 49.14 |
|
| Miragen Therapeutics (VRDN) | 2.2 | $66M | 2.9M | 22.75 |
|
|
| Olema Pharmaceuticals (OLMA) | 2.2 | $66M | -30% | 5.5M | 11.94 |
|
| Arvinas Ord (ARVN) | 1.9 | $58M | -4% | 2.3M | 24.63 |
|
| Y Mabs Therapeutics (YMAB) | 1.8 | $54M | +5% | 4.1M | 13.15 |
|
| Cogent Biosciences (COGT) | 1.7 | $50M | +27% | 4.6M | 10.80 |
|
| Vera Therapeutics Cl A (VERA) | 1.6 | $49M | NEW | 1.1M | 44.20 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 1.6 | $47M | NEW | 932k | 50.42 |
|
| Beigene Sponsored Adr (BGNE) | 1.5 | $45M | NEW | 200k | 224.51 |
|
| Immatics SHS (IMTX) | 1.5 | $45M | +14% | 3.9M | 11.41 |
|
| Apogee Therapeutics (APGE) | 1.4 | $41M | +112% | 702k | 58.74 |
|
| Immunovant (IMVT) | 1.3 | $39M | 1.4M | 28.51 |
|
|
| Cullinan Oncology (CGEM) | 1.3 | $39M | +50% | 2.3M | 16.74 |
|
| Spyre Therapeutics Com New (SYRE) | 1.3 | $37M | NEW | 1.3M | 29.41 |
|
| Pliant Therapeutics (PLRX) | 1.2 | $35M | NEW | 3.1M | 11.21 |
|
| Keros Therapeutics (KROS) | 1.0 | $31M | NEW | 525k | 58.07 |
|
| Erasca (ERAS) | 1.0 | $29M | +47% | 11M | 2.73 |
|
| Oruka Therapeutics | 0.6 | $18M | NEW | 720k | 24.51 |
|
| Perspective Therapeutics Com New (CATX) | 0.4 | $12M | 920k | 13.35 |
|
|
| Compass Pathways Sponsored Ads (CMPS) | 0.2 | $7.3M | -50% | 1.2M | 6.30 |
|
Past Filings by Paradigm Biocapital Advisors
SEC 13F filings are viewable for Paradigm Biocapital Advisors going back to 2021
- Paradigm Biocapital Advisors 2024 Q3 filed Nov. 14, 2024
- Paradigm Biocapital Advisors 2024 Q2 filed Aug. 14, 2024
- Paradigm Biocapital Advisors 2024 Q1 filed May 15, 2024
- Paradigm Biocapital Advisors 2023 Q4 filed Feb. 14, 2024
- Paradigm Biocapital Advisors 2023 Q3 filed Nov. 14, 2023
- Paradigm Biocapital Advisors 2023 Q2 filed Aug. 14, 2023
- Paradigm Biocapital Advisors 2023 Q1 filed May 15, 2023
- Paradigm Biocapital Advisors 2022 Q4 filed Feb. 14, 2023
- Paradigm Biocapital Advisors 2022 Q3 filed Nov. 14, 2022
- Paradigm Biocapital Advisors 2022 Q2 filed Aug. 15, 2022
- Paradigm Biocapital Advisors 2022 Q1 filed May 16, 2022
- Paradigm Biocapital Advisors 2021 Q4 filed Feb. 14, 2022